(19)
(11) EP 2 814 560 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
17.06.2020 Bulletin 2020/25

(45) Mention of the grant of the patent:
06.05.2020 Bulletin 2020/19

(21) Application number: 13749661.8

(22) Date of filing: 13.02.2013
(51) International Patent Classification (IPC): 
A61M 39/10(2006.01)
(86) International application number:
PCT/US2013/025910
(87) International publication number:
WO 2013/123028 (22.08.2013 Gazette 2013/34)

(54)

CONNECTOR

VERBINDER

RACCORD

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 13.02.2012 US 201261598091 P

(43) Date of publication of application:
24.12.2014 Bulletin 2014/52

(73) Proprietor: Yukon Medical, LLC
Durham, NC 27703 (US)

(72) Inventors:
  • PENNY, Matthew R.
    Holly Springs, NC 27540 (US)
  • MOSLER, Theodore J.
    Raleigh, North Carolina 27614 (US)

(74) Representative: Barker Brettell LLP 
100 Hagley Road Edgbaston
Birmingham B16 8QQ
Birmingham B16 8QQ (GB)


(56) References cited: : 
DE-U1- 9 320 713
US-A- 4 810 241
US-A- 5 472 434
US-A1- 2007 088 327
US-A1- 2009 105 692
US-B1- 6 612 624
 DE-U1- 29 818 311
US-A- 5 344 414
US-A1- 2006 271 015
US-A1- 2008 108 956
US-A1- 2011 266 477
US-B1- 6 612 624
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).